



ASX ANNOUNCEMENT

25 March 2025

CARDIEX LAUNCHES NEW CARDIOLOGY REPORT FEATURE IN CONNEQT APP

Cardiex Limited (ASX: CDX) (the **Company**) is pleased to announce the release of a significant new feature in its CONNEQT App - the Cardiology Report - now available on the Apple App Store.

This latest update enhances the app's capabilities by providing users with a comprehensive cardiovascular health assessment, delivering personalized insights into heart and arterial health over time. The Cardiology Report translates clinically validated cardiovascular biomarkers, derived from over 20 years of research, into an easy-to-understand digital format - bringing advanced arterial health and central blood pressure insights directly to consumers.

Designed for individuals focused on proactive heart health management, the Cardiology Report enables users to track key cardiovascular indicators, identify potential risks early, and make informed lifestyle or medical decisions in consultation with healthcare professionals. Through periodic reports and trend analyses, users gain actionable intelligence traditionally only available in clinical settings.

This new feature is expected to drive higher user engagement within the CONNEQT App, by offering visually intuitive reports and risk assessments that encourage ongoing cardiovascular monitoring. Additionally, it establishes the foundation for future in-app monetization opportunities, including premium reports and guided health programs, as Cardiex continues to expand its consumer health ecosystem.

Cardiex CEO Craig Cooper commented:

*"The launch of the Cardiology Report in the CONNEQT App marks an important milestone in our mission to deliver clinical-grade heart health insights directly to consumers. By translating the Pulse's biomarkers measurements into an intuitive, **industry-first**, consumer-facing report, we're enabling individuals to proactively manage their cardiovascular health - beyond the confines of the clinic - while at the same time, providing detailed cardiovascular data that can be shared with a patient's physician to guide treatment options.*

With growing demand for tools that support heart health monitoring at home, this feature directly meets that need. More broadly, it strengthens the CONNEQT App's role as a central hub for personalized cardiovascular insights and further solidifies Cardiex's leadership in the digital transformation of heart health."

With the Cardiology Report now live in the CONNEQT App, Cardiex continues to expand and enrich its digital health ecosystem. The Company's CONNEQT Pulse arterial health monitor, together with the CONNEQT App's new reporting capabilities with the Cardiology Report, offers a comprehensive at-home solution for monitoring and managing cardiovascular health. Cardiex remains committed to translating its clinically validated cardiovascular metrics into accessible consumer tools, further enhancing its mission to improve heart health outcomes through innovative technology.

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations

Rod Hinchcliffe

rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton

melissa.hamilton@mcpartners.com.au

About Cardiex

Cardiex's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor® vascular biomarker technology. Cardiex is listed on the Australian Stock Exchange ("ASX:CDX").